AIM Vaccine (HKG:6660) is looking to raise net proceeds of HK$74.7 million from the placement of 15.5 million shares to Factorial Master Fund at HK$5.01 apiece, a Friday filing with the Hong Kong bourse said.
The shares represent 3.05% and 1.26% of its enlarged H share and issued share capital.
The drugmaker will use proceeds from the issue to accelerate the R&D of various pre-clinical and clinical programs; develop, market, and commercialize new products; and for working capital.
Shares of the company were down nearly 12% in recent trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。